

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
1 June 2017 (01.06.2017)



(10) International Publication Number
WO 2017/091577 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) **G01N 33/574** (2006.01)

(21) International Application Number:
PCT/US2016/063332

(22) International Filing Date:
22 November 2016 (22.11.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/258,731 23 November 2015 (23.11.2015) US
62/314,174 28 March 2016 (28.03.2016) US
62/379,094 24 August 2016 (24.08.2016) US

(71) Applicant: **FIVE PRIME THERAPEUTICS, INC.**
[US/US]; Two Corporate Drive, South San Francisco,
California 94080 (US).

(72) Inventors: **PIERCE, Kristen**; Two Corporate Drive,
South San Francisco, California 94080 (US). **POWERS,
Janine**; Two Corporate Drive, South San Francisco, Cali-
fornia 94080 (US). **PALENCIA, Servando**; Two Corpor-
ate Drive, South San Francisco, California 94080 (US).
SIKORSKI, Robert; Two Corporate Drive, South San
Francisco, California 94080 (US). **GHODDUSI, Majid**;
Two Corporate Drive, South San Francisco, California
94080 (US). **KRISHNAN, Kartik**; Two Corporate Drive,
South San Francisco, California 94080 (US).

(74) Agents: **DOHERTY, Elizabeth A.** et al.; McNeill Baur
PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge,
Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT

(57) Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as anti-bodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or poly-peptides.



WO 2017/091577 A1